Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 5

1.

Infusional mitoxantrone plus bolus melphalan as a stem cell transplant conditioning regimen for multiple myeloma.

Beaven AW, Moore DT, Sharf A, Serody JS, Shea TC, Gabriel DA.

Cancer Invest. 2011 Mar;29(3):214-9. doi: 10.3109/07357907.2010.550663.

PMID:
21314330
2.

Addressing the questions of tomorrow: melphalan and new combinations as conditioning regimens before autologous hematopoietic progenitor cell transplantation in multiple myeloma.

Martino M, Olivieri A, Offidani M, Vigna E, Moscato T, Fedele R, Montanari M, Console G, Gentile M, Messina G, Irrera G, Morabito F.

Expert Opin Investig Drugs. 2013 May;22(5):619-34. doi: 10.1517/13543784.2013.788643. Review.

PMID:
23550793
3.

New developments in conditioning regimens before auto-SCT in multiple myeloma.

Moreau P, Attal M, Harousseau JL.

Bone Marrow Transplant. 2011 Jul;46(7):911-5. doi: 10.1038/bmt.2011.20. Review.

PMID:
21358678
4.

International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma.

Lokhorst H, Einsele H, Vesole D, Bruno B, San Miguel J, Pérez-Simon JA, Kröger N, Moreau P, Gahrton G, Gasparetto C, Giralt S, Bensinger W; International Myeloma Working Group..

J Clin Oncol. 2010 Oct 10;28(29):4521-30. doi: 10.1200/JCO.2010.29.7929.

PMID:
20697091
5.

Allogeneic hematopoietic stem cell transplantation for multiple myeloma: what place, if any?

Giralt S, Koehne G.

Curr Hematol Malig Rep. 2013 Dec;8(4):284-90. doi: 10.1007/s11899-013-0185-y. Review.

PMID:
24146203

Supplemental Content

Support Center